SOURCE: Medistem Inc.

Medistem Inc.

June 15, 2010 23:02 ET

Medistem Heart Failure Publication Achieves "Highly Accessed" Status

Report on Stem Cell Associated Recovery Attracts #1 Views This Year in Medical Journal

SAN DIEGO, CA--(Marketwire - June 15, 2010) -  Medistem Inc. (PINKSHEETS: MEDS). Medistem Inc. reported today that its peer-reviewed publication "Combination stem cell therapy for heart failure" was granted the "Highly Accessed" designation by the medical journal, International Archives of Medicine. To date the manuscript is the top viewed publication for the year. It is available at http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf.

The report describes the rationale for adult stem cell therapy in the treatment of heart failure and reviews numerous successes of this approach in patients reported by other scientists. The paper then describes improvement of a patient with advanced heart failure that was treated using a novel adult stem cell approach developed by the authors. The basis of the paper is to make a case for combination stem cell protocols that are optimized to stimulate the body's own regenerative processes.

"Over a thousand cardiac patients have been treated with adult stem cells in the United States and abroad with favorable safety profile," said Dr. Neil Riordan, senior author on the publication, Chairman of Medistem Inc.

"This new technology is currently in the experimental stages; however, numerous clinical trials have demonstrated statistically significant improvements, which are discussed in our paper," said Dr. Jorge Paz Rodriguez, co-author of the publication and Medical Director of the Stem Cell Institute (www.cellmedicine.com).

Collaborators of Medistem who were co-authors of the paper included internationally-renowned adult stem cell experts from Indiana University, University of Utah, and University of California San Diego.

"Currently adult stem cell therapy is available in the United States as part of clinical trials which are being conducted by companies such as Aldagen, Baxter, Athersys, Amorcyte, and Osiris. In our current paper we provide a blueprint for what we believe will be the next major step in stem cell therapy: the optimization and combination of approaches," stated Thomas Ichim, CEO of Medistem.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Thomas E Ichim
    Chief Executive Officer
    Medistem Inc.
    9255 Towne Centre Drive
    Suite 450
    San Diego CA 92122
    858 349 3617
    858 642 0027
    www.medisteminc.com